This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Nonhyperammonemic, reversible mental deterioration with brain pseudoatrophy in epilepsy children on valproate (VPA)1-4 is rare but potentially underestimated.
VPA may trigger a not-otherwise clinically expressed mitochondrial disease.5 We describe a child who developed severe but reversible behavioral and cognitive dysfunctions with brain pseudoatrophy while receiving VPA. The child carried the rare, known6 heteroplasmic C8393T-Pro→Ser mutation in the MTATP8 gene.
Case report.
A 4-year-old, right-handed, Caucasian boy had an isolated febrile seizure. Since starting primary school, he showed mild learning difficulty.
At age 8 years 1 month, an episode of loss of consciousness was suspected to be of epileptic origin. The CT showed normal patterns. Awake EEG documented focal and diffuse interictal epileptiform abnormalities (IEAs) on normal background activity. After the VPA (18 mg/kg/day), he showed increasing irritability and learning difficulties.
At age 9 years 4 months, neurologic examination was normal. Awake EEG was unmodified (figure, B [a]). Whole-night sleep EEG showed marked activation of IEAs, with continuous spike-and-wave activity lasting up to 3 minutes for about 50% of the slow wave sleep (figure, B [a′]). Gradual VPA increase up to 27 mg/kg/day (serum levels within therapeutic range) coincided with further worsening of school performance and cognitive function.
Figure. (A) MRI. Axial T2- and sagittal …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Alert Me
Recommended articles
A double mutation (A8296G and G8363A) in the mitochondrial DNA tRNALys gene associated with myoclonus epilepsy with ragged-red fibers
Severe epilepsy as the major symptom of new mutations in the mitochondrial tRNAPhe gene
Missense mutation in the mtDNA cytochrome b gene in a patient with myopathy
Multilobar polymicrogyria, intractable drop attack seizures, and sleep-related electrical status epilepticus